RegenXBio (RGNX) AI Stock Analysis

• Market Cap: $409.17M
• Dividend Yield: N/A
• Average Volume (3M): 592.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.14
• Revenue Growth: 74.95%
• EPS Growth: 34.25%
• Country: US
• Employees: 353
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -1.38
• Shares Outstanding: 50,514,217
• 10 Day Avg. Volume: 679,634
• 30 Day Avg. Volume: 592,814
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 2.38
• Enterprise Value/Gross Profit: 2.98
• Enterprise Value/Ebitda: -2.86
• 1Y Price Target: $25.22
• Price Target Upside: 178.37% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 52 Neutral
• Price Target: $9.00 ▼(-0.66% Downside)

RegenXBio's overall stock score reflects significant financial challenges, including declining revenues and negative profitability, which are the most impactful factors. While technical indicators and valuation metrics are weak, recent strategic partnerships and corporate events provide some positive outlook. The earnings call suggests potential for future growth, but regulatory and competitive risks remain.

Positive Factors

Clinical Trial Progress

Enrollment in the pivotal portion of AFFINITY DUCHENNE has surpassed 50%, indicating strong interest in the trial.

Financial Opportunities

REGENXBIO would retain all proceeds from the sale of a Priority Review Voucher, potentially worth $150M.

Regulatory Progress

RGX-121 has received multiple designations from the FDA, including Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy, which can significantly support its approval and commercialization.

Negative Factors

Clinical Safety Concerns

A second acute liver failure-related death in a non-ambulatory DMD patient infused with Elevidys raises concerns in the context of similar therapies.

Market Concerns

Demand for DMD gene therapies is expected to decline due to tempered demand for Elevidys.

Stock Valuation

The current price levels imply little or no value for RGX-202, which suggests potential for market undervaluation.

RegenXBio Business Overview & Revenue Model

Company Description

RegenXBio Inc. is a biotechnology company focused on developing gene therapies for the treatment of various genetic diseases and disorders. The company specializes in its proprietary adeno-associated virus (AAV) gene therapy platform, which is designed to provide long-lasting therapeutic effects by delivering genetic material directly to target cells. RegenXBio's core products include treatments for conditions such as X-linked retinitis pigmentosa, spinal muscular atrophy, and other rare genetic disorders, positioning the company at the forefront of the growing gene therapy market.

How the Company Makes Money

RegenXBio generates revenue primarily through the development and commercialization of its gene therapy products. The company earns money through several key revenue streams, including upfront payments, milestone payments, and royalties from partnerships and collaborations with larger pharmaceutical companies. Notable partnerships, such as those with Novartis and AbbVie, contribute to the company's earnings by providing funding for research and development, as well as access to additional resources for clinical trials. Additionally, RegenXBio may receive milestone payments tied to the successful development and commercialization of its therapies, further enhancing its revenue potential.

RegenXBio Financial Statement Overview

Summary

RegenXBio faces significant financial challenges, with consistent losses and negative cash flows. While the company has a strong cash position, its declining equity and persistent operational losses pose risks. The recent improvement in free cash flow is a positive sign, but overall financial health remains weak.

Income Statement

RegenXBio has experienced fluctuating revenue with a significant decline from 2021 to 2024, followed by a slight recovery in TTM. The company has consistently reported negative EBIT and net income, indicating ongoing operational challenges. Gross profit margins have remained relatively stable, but the net profit margin is negative, reflecting persistent losses.

Balance Sheet

The company maintains a moderate debt-to-equity ratio, suggesting manageable leverage. However, stockholders' equity has decreased over time, indicating potential financial strain. The equity ratio has also declined, reflecting reduced financial stability. Despite these challenges, the company has maintained a strong cash position relative to its debt.

Cash Flow

RegenXBio has faced negative operating and free cash flows, highlighting cash flow challenges. However, there has been a positive trend in free cash flow growth in the TTM period, indicating some improvement. The operating cash flow to net income ratio is unfavorable, reflecting cash flow inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	155.78M	83.33M	90.24M	112.72M	470.35M	154.57M
Gross Profit	124.53M	49.76M	53.03M	58.18M	418.51M	118.85M
EBITDA	-129.93M	-198.23M	-239.46M	-244.24M	169.54M	-96.83M
Net Income	-175.57M	-227.10M	-263.49M	-280.32M	127.84M	-111.25M
Balance Sheet
Total Assets	581.03M	465.99M	573.97M	833.27M	1.11B	708.16M
Cash, Cash Equivalents and Short-Term Investments	323.30M	234.69M	275.26M	364.64M	457.44M	475.74M
Total Debt	271.69M	82.03M	89.29M	94.80M	86.68M	72.65M
Total Liabilities	367.35M	206.34M	262.23M	317.07M	349.61M	330.41M
Stockholders Equity	213.68M	259.65M	311.74M	516.20M	764.30M	377.75M
Cash Flow
Free Cash Flow	-90.71M	-175.56M	-228.37M	-238.21M	134.70M	-80.93M
Operating Cash Flow	-87.89M	-173.13M	-218.41M	-207.49M	218.88M	-54.06M
Investing Cash Flow	-5.16M	103.45M	190.94M	-11.93M	-406.64M	122.76M
Financing Cash Flow	114.84M	92.68M	-34.97M	-28.84M	195.25M	200.21M

RegenXBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGNX, the sentiment is Positive. The current price of 9.06 is above the 20-day moving average (MA) of 8.44, above the 50-day MA of 8.73, and above the 200-day MA of 8.30, indicating a bullish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 55.95 is Neutral, neither overbought nor oversold. The STOCH value of 47.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGNX.

RegenXBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSHA	57 Neutral	$761.05M	―	-51.86%	―	-37.09%	58.96%
AMLX	56 Neutral	$731.17M	―	-87.42%	―	-100.08%	-2.45%
IVA	55 Neutral	$488.33M	―	344.74%	―	-47.32%	-26.67%
RGNX	52 Neutral	$409.17M	―	-62.49%	―	74.95%	34.25%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.27%	22.80%	-2.27%
ERAS	34 Underperform	$441.93M	―	-31.16%	―	―	50.77%

RegenXBio Corporate Events

RegenXBio and AbbVie Amend Collaboration Agreement

On August 5, 2025, REGENXBIO Inc. and AbbVie Global Enterprises Ltd. amended their collaboration agreement to modify the development plan for diabetic retinopathy and enhance investment in the wet AMD program. This amendment includes a revised milestone payment structure, with AbbVie committing $100 million upon the first patient dosed in the Phase IIb/III trial and another $100 million for the subsequent Phase III trial. Additionally, AbbVie will lead a new Phase IIIb study for wet AMD, while REGENXBIO will focus on advancing its gene therapy programs, including RGX-202 for Duchenne muscular dystrophy and RGX-121 for Hunter syndrome, with potential FDA approvals and pivotal trial data expected in the coming years.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.

RegenXBio Holds 2025 Annual Stockholders Meeting

At REGENXBIO Inc.’s 2025 Annual Meeting of Stockholders held on May 30, 2025, several key proposals were voted on. Four individuals were elected as Class I directors to serve until 2028, and PricewaterhouseCoopers LLP was ratified as the independent public accounting firm for the year. Additionally, stockholders approved the executive compensation plan and decided to hold annual advisory votes on this matter. The 2025 Equity Incentive Plan was also approved.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.

RegenXBio Secures $250M Royalty Monetization Deal

On May 16, 2025, REGENXBIO Inc. announced a strategic royalty monetization agreement with HealthCare Royalty Management, LLC, securing up to $250 million in non-dilutive funding through a limited recourse royalty bond. This agreement provides immediate capital of $150 million, extending the company’s cash runway into early 2027 and supporting its late-stage gene therapy programs. The deal allows REGENXBIO to leverage anticipated royalties from products like ZOLGENSMA® and potential future milestones, positioning the company to accelerate commercial preparations and maintain its leadership in gene therapy.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.